Clinical experience with daptomycin in Italy: results from a registry study of the treatment of Gram-positive infections between 2006 and 2009

Utili, Riccardo; Cogo, Alberto; Cristini, Francesco; Prisco, Vincenzo; Sagnelli, E.; Tascini, Carlo; Iacoboni, Cinzia; Capone, Alessandro; Gattuso, Gianni; Angarano, Gioacchino; Petrelli, Enzo; Grossi, Paolo; Bartezaghi, Marta; Zagni, Emanuela

doi:10.1179/1120009x12z.00000000023

Cited by 6 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, no new or unexpected safety findings were observed in this analysis. These safety results are consistent with earlier published real-world reports from the USA and Europe [ 34 , 41 , 55 ].…”

Section: Discussionsupporting

confidence: 93%

Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE

Seaton

Gonzalez-Ruiz

Cleveland

et al. 2016

Ann Clin Microbiol Antimicrob

View full text Add to dashboard Cite

BackgroundPooled data from two large registries, Cubicin® Outcomes Registry and Experience (CORE; USA) and European Cubicin® Outcomes Registry and Experience (EU-CORE; Europe, Latin America, and Asia), were analyzed to determine the characteristics and clinical outcomes of daptomycin therapy in patients with Gram-positive infections across wide geographical regions.MethodsPatients receiving at least one dose of daptomycin between 2004 and 2012 for the treatment of Gram-positive infections were included. Clinical success was defined as an outcome of ‘cured’ or ‘improved’. Post-treatment follow-up data were collected for a subset of patients (CORE: osteomyelitis and orthopedic foreign body device infection; EU-CORE: endocarditis, intracardiac/intravascular device infection, osteomyelitis, and orthopedic device infection). Safety was assessed for up to 30 days after daptomycin treatment.ResultsIn 11,557 patients (CORE, 5482; EU-CORE, 6075) treated with daptomycin (median age, 62 [range, 1–103] years), the most frequent underlying conditions were cardiovascular disease (54.7 %) and diabetes mellitus (28.0 %). The most commonly treated primary infections were complicated skin and soft tissue infection (cSSTI; 31.2 %) and bacteremia (21.8 %). The overall clinical success rate was 77.2 % (uncomplicated SSTI, 88.3 %; cSSTI, 81.0 %; osteomyelitis, 77.7 %; foreign body/prosthetic infection (FBPI), 75.9 %; endocarditis, 75.4 %; and bacteremia, 69.5 %). The clinical success rate was 79.1 % in patients with Staphylococcus aureus infections (MRSA, 78.1 %). An increasing trend of high-dose daptomycin (>6 mg/kg/day) prescribing pattern was observed over time. Clinical success rates were higher with high-dose daptomycin treatment for endocarditis and FBPI. Adverse events (AEs) and serious AEs possibly related to daptomycin therapy were reported in 628 (5.4 %) and 133 (1.2 %) patients, respectively.ConclusionsThe real-world data showed that daptomycin was effective and safe in the treatment of various Gram-positive infections, including those caused by resistant pathogens, across wide geographical regions.

show abstract

Section: Discussionsupporting

confidence: 93%

Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE

Seaton

Gonzalez-Ruiz

Cleveland

et al. 2016

Ann Clin Microbiol Antimicrob

View full text Add to dashboard Cite

show abstract

“… 25 , 26 The safety and tolerability profile and low overall rates of clinical failure were similar to the rates reported around the world. 20 , 22 , 23 …”

Section: Discussionmentioning

confidence: 99%

Brazilian experience in EU-CORE: daptomycin registry and treatment of serious Gram-positive infections

Timerman¹,

Brites²,

Bicudo³

et al. 2013

The Brazilian Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Daptomycin seems to be effective in the treatment of these severe cases owing to its pharmacokinetic and pharmacodynamic characteristics and its fast bactericidal activity with a limited bacterial lysis [12,13]. …”

Section: Discussionmentioning

confidence: 99%

Daptomycin efficacy in the central nervous system of a patient with disseminated methicillin-resistant Staphylococcus aureus infection: a case report

et al. 2012

Self Cite

View full text Add to dashboard Cite

IntroductionStaphylococcus aureus has emerged as a major nosocomial pathogen in the last decades and also represents the second most common pathogen isolated from patients in outpatient settings. Although methicillin-resistant S.aureus infections were traditionally limited to hospitals, community-associated cases of methicillin-resistant S.aureus infections have been reported. In our case, we observed an unexpected event during treatment.Case presentationA 60-year-old Caucasian man developed fever and multiple muscle and brain abscesses caused by Panton-Valentine leukocidin-negative community-associated methicillin-resistant S. aureus.ConclusionAlthough our patient was given antimicrobials active against the isolated methicillin-resistant S. aureus strain, it was only after the introduction of daptomycin that his skin, soft tissue and muscle lesions and also brain manifestations improved.

show abstract

Clinical experience with daptomycin in Italy: results from a registry study of the treatment of Gram-positive infections between 2006 and 2009

Cited by 6 publications

References 28 publications

Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE

Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE

Brazilian experience in EU-CORE: daptomycin registry and treatment of serious Gram-positive infections

Daptomycin efficacy in the central nervous system of a patient with disseminated methicillin-resistant Staphylococcus aureus infection: a case report

Contact Info

Product

Resources

About